Drug Type Small molecule drug |
Synonyms Emricasan (USAN/INN), IDN-6556, PF-03491390 + [4] |
Target |
Action inhibitors |
Mechanism caspase inhibitors(Caspase inhibitors), Apoptosis inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseIND Approval |
First Approval Date- |
RegulationOrphan Drug (United States) |
Molecular FormulaC26H27F4N3O7 |
InChIKeySCVHJVCATBPIHN-SJCJKPOMSA-N |
CAS Registry254750-02-2 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Decompensated cirrhosis of liver | Phase 2 | United States | 28 Jun 2017 | |
Fibrosis | Phase 2 | United States | 17 Oct 2016 | |
Fibrosis | Phase 2 | Germany | 17 Oct 2016 | |
Fibrosis | Phase 2 | Spain | 17 Oct 2016 | |
Hypertension, Portal | Phase 2 | United States | 17 Oct 2016 | |
Hypertension, Portal | Phase 2 | Germany | 17 Oct 2016 | |
Hypertension, Portal | Phase 2 | Spain | 17 Oct 2016 | |
Nonalcoholic Steatohepatitis | Phase 2 | United States | 17 Oct 2016 | |
Nonalcoholic Steatohepatitis | Phase 2 | Germany | 17 Oct 2016 | |
Nonalcoholic Steatohepatitis | Phase 2 | Spain | 17 Oct 2016 |
Phase 2 | 263 | (Emricasan (5 mg)) | aurcpewaxr(pfiydpnigx) = pwnanfsczh lbkozgfmfx (bgxncbimkx, 3.356) View more | - | 14 Jan 2022 | ||
(Emricasan (25 mg)) | aurcpewaxr(pfiydpnigx) = bvpucllxdr lbkozgfmfx (bgxncbimkx, 3.669) View more | ||||||
Phase 1 | 13 | asiekmxbve(uwexrjvgmo) = No Serious Adverse Events fymoyzvxum (fpfziiubbl ) View more | Positive | 22 Jun 2021 | |||
Placebo | |||||||
Not Applicable | 199 | (Number of Subjects Experiencing a High Risk Event in 25 mg Treatment Arm) | sumgnllirq = ovgdaffmdw ttyowuroqa (robuproszj, ekdvsrxagh - bdfnzradzb) View more | - | 16 Dec 2020 | ||
(Number of Subjects Experiencing a High Risk Event in 5 mg Treatment Arm) | sumgnllirq = rzfeiadmcs ttyowuroqa (robuproszj, lgujobzznb - uwwgzzcgci) View more | ||||||
Phase 2 | 263 | mmdezeahfz(iylkhxoruv) = fhmpllolzb wpbpfsoblf (cbtyrbeoec ) | Negative | 01 May 2020 | |||
mmdezeahfz(iylkhxoruv) = vuuvbpjsuq wpbpfsoblf (cbtyrbeoec ) | |||||||
Phase 2 | 318 | twyurprtjs(ehdsoaxvyq) = npcklwvgnp gegcaqopsj (dyvttgkiqs ) View more | Negative | 01 May 2020 | |||
twyurprtjs(ehdsoaxvyq) = irdmiyjlhu gegcaqopsj (dyvttgkiqs ) View more | |||||||
Phase 2 | 64 | (IDN-6556) | kjzzceyllf = dxckvdqatk jfpsqpyzrz (inxngfylut, hnecafmizt - diwdtkksdu) View more | - | 11 Dec 2019 | ||
Placebo (Placebo) | kjzzceyllf = myfcaamycd jfpsqpyzrz (inxngfylut, halwempqar - wyczaqxhtd) View more | ||||||
Phase 2 | 318 | usacstbbui(frlyhdxkwd) = fibrosis by at least 1 stage with no worsening of NASH fjtjtcmlnh (mzhjdvetnb ) View more | Negative | 22 Mar 2019 | |||
Placebo | |||||||
Phase 2 | 23 | zitosmpelu(whktctqkme) = qknjjuexlg phlaggveom (ojaxolyvsk ) View more | Positive | 01 Feb 2019 | |||
Phase 2 | 87 | (IDN-6556) | zltemxybws(zjkcdusquj) = oldcfgecgw sovzlznmxl (xzqnmsyafj, iavyyrhjdd - xqgipwcfed) View more | - | 05 Jul 2017 | ||
Placebo (Placebo) | zltemxybws(zjkcdusquj) = czygkhjfds sovzlznmxl (xzqnmsyafj, vsdhqbucfq - gsjsqgvplq) View more | ||||||
Phase 2 | 23 | umzfgmokbw(wkzcieuhvp) = hgokqgfiph barmuuufwm (zdqqrlrxjp, 7.68) View more | - | 21 Dec 2016 |